01 Rising Prevalence of Chronic DiseasesThe rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions has increased the need for diagnostic instruments capable of early identification and accurate disease monitoring. Biochips enable multiplexed investigation of biomarkers linked with numerous diseases, allowing for more precise diagnosis, prognosis, and individualized treatment selection. As healthcare systems worldwide prioritize illness prevention and management, biochip-based diagnostics are projected to gain traction.Furthermore, biochip-based tests can characterize tumor genomes for somatic mutations, copy number changes, and gene expression patterns, assisting doctors in selecting targeted medicines and tracking treatment outcomes in cancer patients. According to the World Health Organization (WHO), cancer is the world's second most significant cause of mortality, accounting for around one in every six fatalities. Cancer is expected to kill 10 million people by 2023, equating to around 26,300 deaths every day. The cancer burden is predicted to rise by around 60% over the next two decades, putting additional strain on healthcare systems, individuals, and communities. As the worldwide cancer burden increases, so will the demand for biochip technologies for oncology applications, resulting in market expansion in the future years.
01 High Development and Implementation CostThe initial investment for developing biochip technology, which includes research and development costs, equipment expenses, and regulatory compliance, can be significant. Furthermore, the cost of incorporating biochip-based assays into existing laboratory processes, such as staff training, infrastructure modifications, and quality control procedures, may pose barriers to adoption, particularly in resource-constrained environments. Depending on the test, Biochips can cost hundreds to thousands of dollars. For example, the Hydra-1K biochip might cost USD 7 to USD 15 for each test. DNA sequencing is one of the most expensive tests, costing up to USD 700,000.Following research, integrating biochip-based assays in clinical laboratories or healthcare settings necessitates additional investments in infrastructure, training, and quality assurance procedures. Laboratories must purchase biochip instruments, reagents, and ancillary equipment and develop standard operating procedures (SOPs) and quality control techniques. Training laboratory personnel on biochip operation, data analysis, and result interpretation is critical to ensuring accurate and reliable test results. Furthermore, human biochips cost roughly USD 1,000, while chips for mice, yeast, and fruit flies cost between USD 400 and USD 500. The expenses of developing and implementing biochip technologies impede market entrance and acceptance, especially for smaller enterprises and resource-constrained environments.
01 Expanding Applications in Personalized MedicineThe emergence of customized medicine techniques, driven by advances in genomics, molecular diagnostics, and targeted medicines, opens up new prospects for biochip technologies. Biochips allow for the investigation of individual genetic variants, biomarker profiles, and treatment responses, thereby advancing precision medicine projects in oncology, pharmacogenomics, and infectious illnesses. As healthcare systems promote tailored treatment strategies and patient-centered care, the need for biochip-based and companion diagnostics will likely grow. For example, in January 2022, a team of researchers from the Czech Academy of Sciences (CAS) created a device that uses a biochip to identify the COVID-19 virus. According to the researchers, a biochip is as fast as an antigen test and as precise as PCR testing. Combining biochip technology and numerous applications is expected to accelerate biochip market growth.Thus, as personalized medicine becomes more widely used in clinical practice, the need for biochip technologies for molecular and companion diagnostics will likely rise, driving market growth worldwide.
May 2026 Thermo Fisher Scientific expanded its biochip portfolio by introducing next-generation microarray and multiplex assay platforms designed to improve genomic research, clinical diagnostics, and precision medicine applications.
January 2026 Illumina launched advanced biochip-based sequencing solutions featuring enhanced throughput and accuracy to support large-scale genomics and molecular diagnostics.
September 2025 Agilent Technologies expanded its biochip product portfolio with innovative lab-on-a-chip technologies for biomarker discovery, drug development, and life sciences research.
June 2025 Bio-Rad Laboratories introduced upgraded microfluidic biochip systems for rapid nucleic acid and protein analysis, improving laboratory workflow efficiency and diagnostic performance.